Board of Directors
STEFAN LEMPERLE, M.D., Ph.D., MBA
Dr. Stefan Lemperle founded AscentX Medical, Inc. in April 2008 and has since served as the Company's President and CEO. From January 2007 to April 2009, Dr. Lemperle was the President and CEO of Clinicon Corporation, a privately held medical technology company that develops, manufactures and markets fractional CO2 lasers and diamond laser scalpels. In April 1999, Dr. Lemperle co-founded Artes Medical Inc., a NASDAQ-listed medical technology company, which developed and secured FDA approval for the first and only permanent injectable wrinkle filler (ArteFill(R)) (acquired by Suneva Medical, Inc. in 2009). He served as Vice-Chairman of the Board of Directors and President & Chief Executive Officer of Artes Medical Inc. from April 1999 to December 2006. In 1996, Dr. Lemperle co-founded MacroPore Inc. (now Cytori Therapeutics Inc., NASDAQ: CYTX), a medical technology company focused on the design, manufacture and distribution of bio-degradable bone fixation and regeneration devices for craniofacial and spine surgery. He served as Vice-Chairman of MacroPore, Inc.'s Board of Directors, Executive Vice President R&D, and Chief Scientific Officer between 1996-2000.
In August 2014, Dr. Lemperle graduated from Pepperdine University's President & Key Executive (PKE) MBA Program at the Graziadio School of Business and Management. From July 1994 to October 1996, Dr. Lemperle was a post-doctorate research fellow at the University of California, San Diego, Division of Plastic Surgery, sponsored by the Deutsche Forschungsgemeinschaft (DFG) (German Research Society). In 1992, Dr. Lemperle received both his M.D. and Dr. med. (PhD equivalent) degrees from the Johann Wolfgang von Goethe University Frankfurt/Main, Germany where he also trained in general surgery between 1992-1994.
Between 1985-1997, Dr. Lemperle was a regular team member of INTERPLAST Germany, where he participated in yearly reconstructive surgery missions to third world countries throughout the world.
Dr. Lemperle is author/co-author of various scientific publications in the fields of Liver Transplantation, Bone Regeneration, Aesthetic Surgery, GERD and SUI. Dr. Lemperle holds various patents in medical technology. In 2005, Dr. Lemperle was a San Diego finalist for the Ernst & Young Entrepreneur of the Year(R) Awards.
JOHN C. STISKA, J.D.
John Stiska has over thirty years of experience in corporate law, securities law, mergers and acquisitions, and senior management of both publicly and privately held companies. Recently he served as CEO of PepperBall Technologies, Inc. (OTCBB:PBal), and prior to that was the interim CEO of JNI Corp. (NASDAQ:JNIC) and then Chairman until it was merged into Applied Micro Circuits Corp. (NASDAQ:AMCC). From 2000 to 2009, John was an active partner in Commercial Bridge Capital, LLC, a venture lending fund based in San Diego.
From February 1996 to February 1998, he served as Corporate Senior Vice President and General Manager of the Technology Applications Division of Qualcomm Incorporated (NASDAQ: QCOM), a leading developer and manufacturer of telecommunications technology.
Prior to Qualcomm, John was CEO of Triton Group, Ltd (ASE:TGL) a public holding company which he took through a successful Ch 11 reorganization of the former Intermark, Inc. (ASE:IMI). Companies owned or controlled by IMI and TGL included Pier 1 Imports, Simplicity Pattern Co., Continental Graphics, National Arimotive Corp, Western Sizzlin, Liquor Barn, Sunbelt Nursery Group and a number of other companies.
Before joining Intermark, Inc. and Triton Group, Ltd. in 1990, he was a practicing lawyer for 20 years: Partner in the San Diego office of Brobeck, Phleger & Harrison from 1987 to 1990; partner and founder of the corporate department of Aylward, Kintz, Stiska, Wassenaar and Shannahan from 1981 to 1987; and, associate and partner at Luce, Forward, Hamilton & Scripps from 1970 to 1981.
Mr. Stiska has served on numerous public and privately held company Boards of Directors.
He has served on the Boards of Directors of Triton Group, Ltd. (NYSE:TGL ); (ASE:TGL ) and Intermark, Inc. (ASE:IMI), BioSafety Systems, Inc. (NASDAQ:BSSI), IVHS Technologies, Inc., Eaton Vorad, Inc., Jaycor, Inc., PepperBall Technologies, Inc, Laser Power Corp. (NASDAQ:LPWR), Mission West Properties (ASE:MWP), Rehabilitation Technologies, Inc., Ridgewood Properties, Inc. (OTC:RWPI), Sciteq Electronics, Inc., Simplicity Holdings, Inc., Computer Economics, Inc., Stellar Access, Inc., Principia Lightworks, Inc., Midpoint Productions, the Advisory Board of Barney & Barney, LLC and AVAAK, Inc,, the San Diego Corporate Directors Forum, the San Diego County YMCA, Verado Holdings, Inc. (NASDAQ:VRDO), Websense, Inc. (NASDAQ:WBSN), Romer, Inc., JNI Corporation(NASDAQ:JNIC), Cobalt Medical, Inc., AP Labs, Inc., MicroVision Optical, Inc., DR Technologies, Inc., Verras Medical, Inc., Optics Masters, Corp., Venture Holdings and several of its European subsidiaries and Surge Global Energy, Inc. (OTCBB:SRGG), and Armor Designs, Inc.
He is also active in the San Diego Corporate Directors Forum and the San Diego County YMCA.
Mr. Stiska received the Award of Director of the Year for Companies in Transition from the Corporate Directors Forum of San Diego.
He received his BBA in Accounting from the University of Wisconsin, and after serving as an officer in the Army returned to get his JD from the University of Wisconsin Law School. He is licensed to practice law in California.
RUSSEL ANDERSON, M.S. PharmE, MBA
DIRECTOR, EXEC VP ENGINEERING & PRODUCT DEVELOPMENT, CTO
Since October 2010, Mr. Russell Anderson has served as President and Board member of Biostratus Corporation, a biomedical development and consulting firm. From January 2009 to October 2010, Mr. Anderson served as Program Director and Vice President of Product Development and Engineering at Lithera, Inc., a San Diego based Pharmaceutical and Biomedical Technology Company. From January 2004 to November 2008, Mr. Anderson served as the Vice President of Manufacturing & Engineering and Vice President of Product Development & Engineering at Artes Medical Inc., a publicly held medical technology company that developed ArteFill®, the first and only permanent injectable wrinkle filler to gain FDA approval. From 2002 until recently, Mr. Anderson was the President and a Principal Engineer of Anderson Biomedical Consulting and his corporate clients included Johnson & Johnson (Ethicon), Amgen, Genentech, Novartis, Sandoz, Roche, NuVasive, Boston Scientific, Collagen Corporation, Target Therapeutics, Vascular Innovations, Alliance Pharmaceuticals, and Stemedica amongst others.
Prior to founding Anderson Biomedical Consulting, he held management positions at Mentor Corporation, Medtronic, Keravision, Cohesion Technologies, and Novare Surgical. In 2009, Russell finished at the top of his class while earning a Master’s of Science degree in PharmME from the Stevens Institute of Technology. He also holds additional graduate certifications in Biologics and Biopharmaceutical Processing, as well as Pharmaceutical Manufacturing Management. In 2000, Mr. Anderson received a Master’s Degree with honors in Business Administration from California State University, Hayward, with concentrations in Production & Operations Management, Technology and Innovation Management, and International Business Management. Mr. Anderson also received a BSEnvE/BSME from California Polytechnic State University at San Luis Obispo. Russell has authored or co-authored dozens of domestic and international issued and pending biomedical patents, and he has also co-authored multiple papers on tissue treatment technologies that have been published in peer reviewed journals.
PROF. GLEN LEHMAN, M.D.
Since 1987 Professor Glen Lehman has served as a Professor of Medicine & Radiology, Division of Gastroenterology/Hepatology at the Indiana University School of Medicine, Indianapolis, Indiana. Professor Lehman served or has served as a consultant to various healthcare companies including Glaxo Smith Kline, Eli Lilly, AstraZeneca, Hoffman LaRoche, Enteric Medical, Wilson-Cook, Bioform, Endonetics, Olympus America, Boston Scientific.
From 1969 to 1972, Professor Lehman performed his residency and fellowship (Gastroenterology) at the Indiana University Medical Center. From 1968 to 1969 he performed an internship at Duke University. Professor Lehman received his M.D. from Indiana University School of Medicine in 1968.
In 1996 Professor Lehman was the recipient of the Rudolf Schindler Award presented by the American Society for Gastrointestinal Endoscopy.
PROF. GOTTFRIED LEMPERLE, M.D., PH.D.
Professor Gottfried Lemperle joined AscentX Medical, Inc. as a co-founder in October 2008 and currently serves as the Company's Chief Medical Officer. Dr. Lemperle was a Voluntary Clinical Professor at the University of California, San Diego School of Medicine, Department of Surgery, Division of Plastic Surgery from 1998 to 2010. In April, 1999, Professor Lemperle co-founded Artes Medical Inc., a publicly held medical technology company based on his invention of the PMMA microsphere platform technology leading to the first and only FDA approved permanent injectable wrinkle filler (ArteFill®) in 2006. He served as Chief Scientific Officer of Artes Medical Inc. from August 1999 to May 2006. Prior to Artes Medical, Professor Lemperle spent over 30 years as Professor & Head of the Division of Plastic & Reconstructive Surgery at the University of Frankfurt/Main, Germany.
Professor Lemperle was awarded M.D. and Ph.D. degrees in Immunology and General and Plastic Surgery from Frankfurt University. He has authored more than 270 original publications in the fields of Plastic Surgery, GERD and SUI.
In 1997 Prof. Lemperle received the Cross of Merit 1st Class (Bundesverdienstkreuz 1. Klasse) from the President of the Republic of Germany for his achievements as founder of INTERPLAST Germany, a non-profit organization providing reconstructive surgery services in third world countries around the world. In 2010 Prof. Lemperle received the Dieffenbach-Medal as a German Lifetime Award for his contributions to the field of Plastic & Reconstructive Surgery.